WELCOME TO FIERCE LIFE SCIENCES WEEKLY DIGEST It’s a tough time for biotech: VC funding and M&A are tightening up, with layoffs seen across the board. But the science continues. Lab vacancies fell to 5.3% in the first quarter of year, while Boston alone lists more than 13.6 million square feet under construction and 135 tenants seeking space to do their work. San Francisco, San Diego and Research Triangle Park are also buzzing. Our report on the top biotech hubs of 2022 tracks some of the areas where the biggest companies are still spreading out, hiring and making breakthroughs. | |
|
Featured Story | By Annalee Armstrong Just when biotechs could use cash the most, the well has dried up. Venture financing deal value for U.S.-based biotechs fell by 46% in the first quarter, compared to the same period a year ago, according to GlobalData. read more |
| |
|---|
|
Top Stories Of The Week By Angus Liu Novartis is buying a pass to expedite FDA review for a future drug application. For $100 million, the Swiss pharma is acquiring a priority review voucher from opioid crisis-crippled Mallinckrodt. read more By Annalee Armstrong It’s a tough time for biotech. A market correction underway. Layoffs have beset the sector. And funding as well as M&A are down across the board. But that doesn’t mean there isn’t plenty going on in labs around the country. We recap the top biotech hubs across the U.S. read more By Fraiser Kansteiner For months, the industry has waited patiently as Novartis mulls the fate of its $25 billion generics arm. Now, it appears a spinoff could be in the cards. read more By Andrea Park Medtronic is now the proud owner of a handful of left-heart access devices, designed to help surgeons make the journey from the right atrium of the heart to the left in procedures for left-atrial appendage closure, mitral valve repair, atrial fibrillation ablation and more. read more By Zoey Becker Even as Amarin's Vascepa is under siege from generics in the U.S., a new analysis raises questions about the company's key cardiovascular drug. read more By Annalee Armstrong Biogen and Eisai’s follow-up to the Alzheimer’s disease treatment Aduhelm scored priority review under the FDA's accelerated review pathway, with a decision slated for Jan. 6. read more By Zoey Becker Pfizer will be able to use Touchlight's "doggybone DNA" technology to produce mRNA vaccines and more thanks to a new licensing agreement. read more By Max Bayer Vertex is restarting the engine of the phase 1/2 trial of its Type 1 diabetes med after the FDA lifted a clinical hold placed in May. The trial was originally paused after the agency said it didn't have enough evidence to support dose escalation. read more By Ben Adams Who's tops in ESG? Patient groups rank Roche, Pfizer and ViiV as the leading companies for their work toward improvements in environment, social and governance issues. read more By Gabrielle Masson A new surprise discovery could hold big implications for muscular dystrophy patients, with researchers finding that an existing cancer drug may delay progression of the hard-to-treat disease. read more By Teresa Carey This week on "The Top Line," we discuss proposed reforms to FDA’s accelerated approval program—and what the biotech industry has to say about them. The Fierce team gets creative with our own biopharma competition. Plus, news from Vertex, Biogen and Eisai, Orchestra and more. read more Resources Sponsored by: Catalent Pharmaceutical drug developers continue to realize the strong therapeutic potential of highly potent active pharmaceutical ingredients (HPAPIs). This is particularly true for therapeutic areas such as oncology, where highly potent drugs are becoming more commonplace. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Catalent Pharmaceutical development companies face several challenges when developing orally bioavailable formulations of active pharmaceutical ingredients. Up to 70% of new drug molecules are poorly soluble in gastrointestinal fluids and can exhibit poor absorption across the gut wall. Sponsored by: Blue Matter Consulting For an emerging biopharma company, Europe can be very attractive. But it can also be complex and confusing. This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities | 
